The breast lesion localization market was USD 410.4 million in 2023, which will reach USD 653.1 million by 2030, powering at a rate of 7% by the end of this decade.
 |
| To learn more about this report: https://bit.ly/47mjZiw |
This is because of the increasing breast cancer screening programs and better compensation conditions. Furthermore, breast cancer is the most prevalent disease in females and its incidence is increasing fast. For example, as per the data published by the IARC, breast cancer has now exceeded lung cancer as the most frequently diagnosed cancer all over the world.
The wire guided category led the industry, with a share of 40%, in 2023. This is because of its low cost, ease of usage, and the obtainability of numerous wire localization devices able to be connected to radiology imaging systems with the use of guided wire.
Also, it is expected that the benefits of the wire localization method, for example its affordability, precision, and efficiency, as opposed to other breast lesion localization procedures, will advance the method's acceptance.
Furthermore, the growing incidence of breast malignancy, the increasing count of breast operations, and the surging usage of the wire localization technique in diagnostic and therapeutic areas are powering the need for early detection and effective treatment, which will further drive the growth of the industry.
In 2023, the breast biopsy category had a larger market share, of 65%, and the requirement for breast biopsies will increase in the years to come. This is for the reason that the metrics are valued as per the volume of patients experiencing breast biopsies and the increasing consciousness of the benefits of a biopsy for early breast lesion diagnosis.
The lumpectomy category also has a considerable share in the industry. This has a lot to do with the benefits of lumpectomy, for example patients’ breasts’ appearance and sensation can be preserved and it has a minimally invasive nature and fast recovery. Thus, it is regularly preferred over other highly invasive procedures like mastectomy.
North America breast lesion localization market is the leader of the pack. This is because of the presence of an established healthcare system, the presence of notable manufacturers, increased consciousness of early discovery of breast cancer, simple FDA approval procedures, and high utilization of advanced devices in cancer treatment facilities, in the region. For example, MOLLI Surgical Inc. got the approval from the U.S. FDA in May 2021 for MOLLITM, a novel wire-free localization technique for breast cancer surgery.
It is due to the increasing occurrence of cancer all over the world, the demand for breast lesion localization is on the rise, and this trend will continue in the years to come as well.
